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ABSTRACT: An unexpected side effect of some classes of anticoagulants has been osteoporosis which may be, at least in part, related
to deranged mesenchymal stem cell (MSC) function. The aim of the present study was to compare the effect of fondaparinux (FDP),
a novel antithrombotic with a traditional widely used low molecular weight heparin, tinzaparin (TZP) on MSC proliferation and
differentiation. MSCs were isolated from trabecular bone of 14 trauma patients by a collagenase-based digestion procedure and
expanded in standard conditions until passage 3. Proliferation and differentiation of MSCs to chondrocytes and osteoblasts was
assessed with or without the addition of FDP and TZP using standard in vitro assays and a broad range of drug concentrations. Flow
cytometry was used for MSC phenotyping. In the age studied group (17–74 years old) the MSC frequency in collagenase-released
fractions was 641/10
6 cells (range 110–2,158) and their growth characteristics were  4 days/population doubling. Cultures had a
standard MSC phenotype (CD73þ, CD105þ, CD146þ, CD106þ, and CD166þ). Cell proliferation was assessed by both colony-forming
unit-ﬁbroblast (CFU-F) and colorimetric tetrazolium salt XTT assays. In both assays, MSC proliferation was inhibited by the
addition of TZP, particularly at high concentrations. In contrast, FDP had no effect on MSC proliferation. Osteogenic differentiation
and chondrogenic differentiation were not affected by the addition of either TZP or FDP. Whilst MSC proliferation, but not
differentiation, is negatively affected by TZP, there was no evidence for adverse effects of FDP in this in vitro model system
which argues well for its use in the orthopedic setting.  2011 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.
J Orthop Res 29:1327–1335, 2011
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A complication of fractures, deep vein thrombosis
(DVT), leads to pulmonary embolism (PE) with up to a
28% DVT incidence being reported post-fractures.
1
Tromboprophylaxis in patients undergoing surgery
with unfractioned heparins (UFH) and, more recently,
low-molecular-weight heparins (LMWHs) signiﬁcantly
reduce the risk of DVT.
2–4 The use of anticoagulants
and UFH in particular has been associated with
systemic osteoporosis which is a known risk factor
for poor fracture healing. Osteoporosis is endemic in
developed and regardless the cause, osteoporosis
results from superseding activities of osteoclasts
compared to osteoblasts.
5 Other factors associated
with impaired healing of 5–10% of the million or so
fractures seen in the UK each year
6,7 are the absence
of adequate mechanical stability, infection, diabetes,
smoking, high alcohol intake, and pharmacological
agents.
8–10 With regard to the effect of LMWHs on
bone metabolism, several animal and in vitro studies,
have reported a negative effect on bone formation.
11–13
It appears that the risk may be decreased by using
LMWH instead of UFH
11 but the effect is not
abolished.
12,13
Another anticoagulant that has been recently
introduced in the clinical setting is fondaparinux
(FDP), a novel antithrombotic that has the speciﬁc
ability to inhibit factor Xa. In vitro studies
14,15
have been performed comparing its effect on bone
metabolism with previously used LMWHs (Enoxaparin
and Dalteparin) and these have shown that FDP
did not have a negative effect on human osteoblast
proliferation in contrast to Enoxaparin and Dalte-
parin. However, to the best of our knowledge, no study
has been performed to evaluate the effects on
bone differentiation of another wide-used LMWH,
Tinzaparin (TZP).
Mesenchymal stem cells (MSCs) are highly prolifer-
ative stromal cells that are capable of forming bone
and cartilage both in vitro and in vivo and may play
an important role in bone health by contributing to
the osteoblast pool of cells. The aim of this study there-
fore was to investigate and compare the effects of FDP
with TZP on proliferation and differentiation of MSCs
derived from trabecular human bone.
MATERIALS AND METHODS
Preparations of Drugs
The antithrombotic drugs used in this study were FDP
(GlaxoSmithKline 2.5 mg, Middlesex, UK), a new antithrom-
botic drug that inhibits factor Xa speciﬁcally, and TZP (LEO
Pharmaceutical Products, 3,500 International Units, Buck-
inghamshire, UK), one of the most commonly used drugs for
the prevention and treatment of DVT. The MSC response to
FDP was studied at its peak plasma concentration obtained
on doses most commonly used for prophylaxis after a frac-
ture
14 as well as at several higher concentrations (latter were
used for conducting the tests because of the accumulation
and resulting higher concentration in the bone in long-term
therapy). TZP PC dosage was obtained from on-line Pharma-
cogenomics knowledge base (http://www.pharmgkb.org/do/
serve?objId¼PA451694&objCls¼Drug). Stock solutions were
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medium (Miltenyi Biotec, Bisley, UK) to make the following
dilutions: TZP 0.5 IU/ml (plasma concentration, PC), 5 IU/ml
( 10) and 50 IU/ml ( 100); FDP 0.34 mg/ml (PC), 3.4 mg/ml
( 10) and 34 mg/ml ( 100). Half-media changes with
both drug preparations were performed every 48 h. Cells
incubated in medium without drugs were used as controls.
Cell Extraction from Trabecular Bone Pieces
MSCs were isolated from iliac crest bone chips obtained
during trauma surgery. In total, 14 individuals participated
in the study (Table 1). All patients were suffering from
pelvic fractures but were otherwise healthy individuals. All
patients provided informed consent while approval from the
local ethics committee was obtained for all samples.
MSCs were extracted from bone chips by collagenase
digestion technique as previously described.
16,17 Brieﬂy,
 0.1 g bone pieces were transferred in Eppendorf microtubes
containing 0.5 ml of 0.25% collagenase (Stem Cell Technol-
ogies, Vancouver, Canada) and cell extraction by tissue
digestion was performed for 4 h at 378C. Released cells were
ﬁltered through 70 mm Cell Strainer (BD Biosciences, San
Jose, CA) and counted using Trypan Blue staining
(Sigma, Dorset, UK). The average number of cells recovered
per sample was 12   10
6 (range 3–31   10
6, Table 1).
Standard Colony-Forming Unit-Fibroblast (CFU-F) Assay to
Measure the Number of MSCs in Collagenase-Released Cell
Fractions
One million collagenase-released cells was placed overnight
into triplicate 25 cm
2 tissue culture ﬂasks in DMEM/10%
FCS (Invitrogen, Paisley, UK) to allow adherent cell
attachment, as described previously.
17 Next day medium
was changed to the non-hematopoietic expansion medium
(Miltenyi Biotec). Cells were next grown in the NH expansion
medium with twice-weekly half-media changes and stained
with 1% w/v Crystal Violet (Sigma) on the 14th day of
culture as previously described.
18 Half-media changes were
performed so culture conditions would not be dramatically
altered after each feeding, by retaining stable levels of
soluble endogenous-produced growth factors and proteins.
Individual colonies were scored by microscopic examination
at low power ( 50). Antibiotics 1% penicillin/streptomycin
(Invitrogen) were used in all in vitro experiments.
Isolation and Expansion of Collagenase-Released MSCs
For this, 20   10
6 collagenase-released cells were similarly
adhered overnight in 25-cm
2 ﬂasks in DMEM/10% FCS.
Next day, adherent cells were placed in 5 ml of non-hemato-
poietic expansion medium and cultures were grown to
conﬂuence with twice-weekly half-media changes. Initial
conﬂuent ( 80%) cultures were designated passage 0 (p0)
and subsequent was performed as 1:2 splits until passage 3
(p3). For passaging MSC cultures were lifted off using Tryp-
sin-EDTA solutions (Invitrogen) as previously described.
17,19
Proliferation and differentiation assays were performed
using p3 cultures.
Flow Cytometry to Conﬁrm the MSC Nature of Bone-Derived
Cultures
MSC marker phenotyping was performed on p3 cultures as
previously described.
18,19 CD13-FITC and CD105-PE were
from Serotec (Kidlington, UK), CD45-FITC was from DAKO
(Ely, UK), CD106-PE, CD73-PE, CD146-PE, and CD166-PE
were from BD Bioscience (Oxford, UK), and all isotype-
speciﬁc negative controls were from Serotec. Three-color
ﬂow cytometry was performed on a BD FACScan. Dead cells
were gated out based on propidium iodide exclusion (Sigma).
Analysis of MSCs Proliferation
The effect of drugs on MSC proliferation was performed
using CFU-F and XTT assays on p3 cultured MSCs as
Table 1. Patient’s Participation and Sample Characterization
a
Sample ID Sex Age Cells per Sample, 10
6 CFU-Fs per 10
6 Cells
Days
p0
b p0–p1 p1–p2 p2–p3
2 F 70 NT NT 11 3 3 3
3 M 24 10 641 9 5 4 3
4 F 57 31 2,158 6 5 5 3
5 F 74 NT NT 8 7 8 5
6 F 70 NT NT 8 7 8 5
7 M 43 25 140 17 3 5 4
8 M 64 NT NT 17 11 10 11
9 M 55 12 874 21 3 4 4
10 M 25 5 273 14 2 2 4
11 M 61 3 110 19 4 7 13
12 M 52 17 417 11 4 4 2
13 F 39 21 1,700 7 3 4 6
14 M 17 5 750 10 8 9 6
1 6 M 4 4 N T N T 1 0 922
Median 54 12 641 11 5 5 4
Range 17–74 3–31 110–2,158 6–21 2–11 2–10 2–13
NT, not tested.
aInclusion criteria: Age of 17 years or greater, adequate neurovascular status, absence of infection and systemic diseases (diabetes,
rheumathoid arthritis, etc). Exclusion criteria: severe hepatic and renal impairment, pregnancy and lactation, non-unions resulting
from bone diseases, dementia, pathological fractures, cancer, systemic treatment for osteoporosis.
bInitial conﬂuent ( 80%) cultures
were designated ‘‘passage 0’’ (p0) and subsequent passaging was performed as 1:2 splits until passage 3 (p3).
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20,21 In CFU-F assay, 500
p3 MSCs were initially seeded into triplicate wells of six-well
plates in DMEM/10% FCS to allow overnight adherence
without drug interference. Next day media was changed to
an appropriate drug-containing or control expansion media
and cells were grown for further 7 days. In the treatment
group a broad of drug concentrations, from PC to 100-fold
higher was used to determine age-dependent effects and
in control group MSCs were expanded normally. MSC
proliferation was assessed by manual counting of colonies
formed 7 days after plating as previously optimized.
17,21
Colonies were stained with Crystal violet and triplicates
were averaged for each treatment group. Additionally, the
number of cells per colony was counted for 10 random colo-
nies in each treatment group and averaged. In the XTT
assay cell proliferation was indirectly assessed by measuring
metabolically active cells, as optimized previously.
20,21 In this
assay 500 p3 MSCs were seeded in quadruplicate wells of 96-
well plates in DMEM/10%FCS. Similarly to CFU-F assay,
media was changed 24 h later to drug-containing expansion
media and MSCs were allowed to grow for further 7 days.
Optical density was measured after the addition of the XTT
reagent (Roche Diagnostics, Welwyn Garden City, UK). Inhi-
bition of MSC proliferation was assessed as a reduction in
optical density (OD) compared to no-drug control.
20,21
Osteogenic Differentiation Assay
Alkaline phosphatase (ALP) assay, Alizarin Red (AR) stain-
ing for mineralized matrix and calcium production assay
were used to evaluate the osteogenic potential of MSCs. In
all experiments osteogenesis was induced in 3   10
4 p3
MSCs using commercial osteoinductive medium OsteoDiff
(Miltenyi Biotec). The effects of FDP and TZP were compared
using cells from the same four donors (aged 17–52). MSCs
were initially adhered in triplicate 35-mm round dishes in
DMEM/10% FCS and next day media was changed to Osteo-
Diff with or without appropriate dilutions of drugs. Differen-
tiation was induced for a maximum of 3 weeks with half-
media changes twice a week. ALP, AR, and calcium assays
were performed as previously described.
18,21 Brieﬂy, ALP
staining was performed on day 14 post-induction using Fast
RR Blue Salt (Sigma). Calcium was extracted on day 21 post-
induction using 1 ml of 0.5 N HCl/well and measured using
Ca
þþ assay (Thermo, Cramlington, UK) and Calcium/Phos-
phorus standard (Sigma). The purple color was read using
570 nm ﬁlter on a GENios Microplate Reader. For AR assay,
cells were ﬁxed with cold ethanol and stained with AR (pH
4.1) at room temperature (RT). After ﬁve washes in distilled
water, dishes were air-dried and scanned. All assays were
performed in triplicate for each drug dilution.
Chondrogenic Differentiation Assay
In this assay, 0.25   10
6 p3 MSCs were initially pelleted d-
own in quadruplicate 1.5 ml Eppendorf tubes and placed in
0.5 ml of commercial chondroinductive ChondroDiff medium
(Miltenyi Biotec) with or without drugs. Caps were loosened
to allow air exchange. Cell pellets were fed three times per
week with half-medium changes. On day 21, three pellets
were assayed for sGAG content after digestion with 1 mg/ml
Papain (Sigma,) using a commercially available assay
(Wieslab AB, Boldon, UK) as previously described.
18,21
The blue color was read using 630 nm ﬁlter on a GENios
Microplate Reader. A standard curve was built using assays’
calibrators of known sGAG content (included in the kit). The
remaining pellet was processed for staining with 1%
Toluidine blue (Sigma), as previously described.
18,19
Statistical Analysis
All calculations were done on using the SPSS software
standard version 13.0 for Windows. Data are expressed
as means (standard deviation) or median (range) as appro-
priate. Matched paired data (without and with the addition
of drugs) were compared using nonparametric Wilcoxon
paired test and Spearman test was used for testing age-
dependency. The cut-off value for signiﬁcance was p ¼ 0.05.
RESULTS
Characterization of Bone-Derived MSCs
As seen in Table 1, the concentration of MSCs
(measured by the CFU-F assay) in the collagenase-
released cellular fraction was not age-dependent
and within previously published ranges.
17 The pro-
liferation kinetics of MSCs was measured up to p3 and
the average time required for MSCs to reach p0
was 10 days. The population doubling time between
subsequent passages was on average 4 days (range 3–
6 days), consistent with our previously published data
for similar age group.
17
The procured cultures possessed adipogenic
differentiation capacity (data not shown) and had a
surface phenotype consistent with MSCs: a mean of
99% cells positive for CD73, 98.5% cells positive for
CD105, 99% positive for CD166, 85% positive CD146,
59% positive for CD106, 96.5% positive for CD13 and
negative for CD45 (Fig. 1). Therefore, p3 bone-derived
cultures had growth kinetics and the phenotype
consistent with MSCs.
The Effects of TZP and FDP on MSC Proliferation
The effects of drugs on MSC proliferation were
assessed using a standard CFU-F assay on cultured
MSCs and the XTT assay.
20,21 Although CFU-F assay
remains fairly subjective, it accurately measures the
Figure 1. The marker phenotype of MSC cultures grown from
human trabecular bone. Error bars represent SD (n ¼ 5 donors,
selected to cover age range 17–70 years old). The results show
cell surface phenotype consistent with MSCs (CD73þ, CD105þ,
CD166þ, CD146þ, CD106þ, CD13þ, and CD45 ).
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cells.
21 The average CFU-F of p3 MSCs was 6.5%
(range 2.2–12.2%, n ¼ 6), consistent with previously
published data
17 indicating that the remainder were
less-proliferative progenitor cells.
22 On the other hand,
XTT assay provides highly reproducible read-outs, but
the results represent the effects of compounds on both
highly proliferative and less-proliferative cells, as XTT
binds to all metabolically active cells. In combination,
these assays accurately reﬂect the effects of the com-
pounds on MSC proliferation in the whole culture. The
results for both assays are presented as a percent inhi-
bition of CFU-F formation or inhibition of ODs, com-
pared to ‘‘no drug’’ controls (Figs. 2 and 3). Although
the dose of drugs used at the cellular level and the
growth kinetics of the cells in the culture wells could
be different between CFU-F and XTT assay, similar
trends were observed.
As shown in Figure 2, MSC proliferation was
inhibited by TZP. CFU-F assay revealed statistically
signiﬁcant inhibition (p < 0.05) at all concentrations of
TZP, whereas in the XTT assay statistically signiﬁcant
inhibition (p ¼ 0.036) was achieved at the highest
concentration of TZP (X100). The size of colonies in
the CFU-F assay, measured as the number of cells per
colony, was also inhibited by media supplementation
with TZP (Fig. 2). In contrast, MSC proliferation
was not affected by the addition of FDP, at any con-
centration of the drug, as evidenced by both CFU-F
and XTT assays (Fig. 3). Altogether these ﬁndings
Figure 2. The effects of TZP on MSC proliferation using the CFU-F assay (top and middle panels) and XTT assay (bottom panels).
Individual donor-derived cultures are shown on the left and combined results for all donors (mean   SD) are shown on the right. Dose-
dependent inhibition of MSCs proliferation is observed using both assays.  p < 0.05.
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MSC proliferation by the addition of TZP, particularly
at high concentrations. In contrast, FDP had no effect
on MSC proliferation.
Osteogenic Differentiation
The effects of FDP and TZP on MSC osteogenic
differentiation were assessed using p3 MSCs. A
negative trend was observed between the age of donor
and calcium production by p3 MSC cultures (r
2 ¼
 0.6, p ¼ 0.07) and to avoid age-dependent effects,
FDP and TZP were tested using cells from the same
four donors. ALP activity and Calcium production
were assessed at their peak levels on days 14 and 21,
respectively (Fig. 4A). As seen in Figure 4B, the
addition of both FDP and TZP in osteogenic medium
did not affect ALP activity. Similarly, the addition
of TZP or FDP to OsteoDiff showed no inhibition of
mineralization, evidenced by AR staining (Fig. 4B).
Consistent with ALP and AR staining, calcium pro-
duction was not affected by the addition of neither
TZP nor FDP (Fig. 4C). Altogether, these results
demonstrated no deleterious effects of TZP or FDP
concentrations on the osteogenic differentiation of
MSCs in vitro.
Chondrogenic Differentiation
The average sGAG production p3 MSC cultures
on day 21 post-induction was 4.5 mg/pellet (range 3.8–
16.6, n ¼ 3 donors), consistent with previously pub-
lished results.
20 As shown in Figure 5A, no statisti-
cally signiﬁcant decrease in the sGAG/pellet was
observed if media was supplemented with TZP.
Similar results were obtained for ChondroDiff supple-
mented with FDP (Fig. 5B). Figure 5C illustrates the
lack of chondrogenesis inhibition by FDP by staining
chondrogenic pellets with Toluidine Blue. Altogether,
these data showed that neither TZP nor FDP had any
effect on chondrogenic differentiation of MSCs in vitro
supporting the idea that these molecules are unlikely
to affect the endochondral ossiﬁcation pathway which
is important in fracture repair.
DISCUSSION
In the present work we compared the effects of FDP
and a widely used LMWH, TZP on MSC function in
Figure 3. The effects of FDP on MSC proliferation using the CFU-F assay (top and middle panels) and XTT assay (bottom panels).
Individual donor-derived cultures are shown on the left and combined results for all donors (mean   SD) are shown on the right. No
dose-dependent inhibition of MSCs proliferation is observed using both assays.
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son of these two drugs using the same donor-derived
cells has not been previously performed. Our results
revealed that neither anticoagulants affected MSC
osteogenesis and chondrogenesis. However unlike
TZP, FDP did not inhibit MSC proliferation and
hence was superior to TZP in terms of its effects on
MSC proliferation potential in vitro.
Previous in vitro experiments have documented
negative effects of some LMWHs on human osteo-
blasts. One study showed the superiority of FDP
compared with other LMWHs Dalteparin and Enoxa-
parin in respect to mitochondrial activity and protein
synthesis by osteoblasts in vitro.
15 Enoxaparin and
Dalteparin, on the other hand, led to a signiﬁcant
decrease of matrix collagen content and calciﬁcation
by osteoblasts, in concentrations equal or higher than
the therapeutic dose. Of note, osteoblast cultures in
the above study were derived from a distal femur
bone of elderly patients with arthritis. In our study,
the effects of FDP and TZP were investigated on the
osteoblast precursors, namely MSCs, generally in a
younger population group. The choice of MSCs as
target cells was relevant to a clinical situation of frac-
ture when both proliferation and correct differen-
tiation of immature MSCs is needed for a biological
healing cascade to occur in a timely and efﬁcient
manner.
23 In the ﬁrst part of our study we indeed
conﬁrmed that cultures derived from normal trabecu-
lar bone had growth characteristics and the phenotype
consistent with MSCs.
16,17,24,25 We acknowledge that
further work is needed to establish the effects of FDP
and TZP on osteoblasts, and not only MSCs.
Handschin et al.
14 reported a signiﬁcant dose-
dependent inhibition of osteoblast proliferation follow-
ing the administration of Dalteparin to human osteo-
blasts in vitro whereas no inhibitory effects were
observed in the FDP treated group. It is noteworthy
that unlike other studies focused on total number
of osteoblasts in culture, Handschin et al. investigated
osteogenesis by reverse transcriptase-polymerase
chain reaction for the expression of osteogenesis-
related genes (osteocalcin, collagen type I, and ALP).
In our study we used long-term functional assays of
osteogenesis and chondrogenesis and were able to
measure the effects of FDP and TZP on MSC
Figure 4. The effects of TZP and FDP on MSC osteogenesis. (A) Osteogenesis assay time course in control p3 MSCs. Top panel, ALP
activity; bottom panel, Alizarin Red staining. (B) day 14 ALP activity (left) and day 21 Alizarin Red staining (right) with the addition of
FDP and TZP. (C) day 21 calcium production. Top panel shows individual donor-derived cultures and bottom panel shows combined
results for three donors (mean   SD). No effect of both drugs on ALP activity and mineralization was found. Representative exper-
iments are shown for ALP and Alizarin Red staining. [Color ﬁgure can be seen in the online version of this article, available at http://
wileyonlinelibrary.com/journal/jor]
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found to have no deleterious effects on MSC osteogen-
esis. Furthermore, our study provided ﬁrst evidence
that FDP was well tolerated not only by osteoblasts,
but also by MSCs. Previously we showed inhibitory
effects of NSAIDs on the MSC chondrogenesis using
similar functional assays and it appears that these
assays represent a robust way of assessing pharmaco-
logical agents relevant to orthopedics in vitro.
20 In
this study we performed end point differentiation
assays and did not test the effects of drugs throughout
the culture period, which could have been more
informative, but necessitated signiﬁcant expansion of
cells leading to the loss of potency.
26 Small donor
group size for osteogenesis and chondrogenesis
represents another limitation of this study. On the
other hand, the fact that we used several independent
assays for proliferation, osteogenesis, and chondrogen-
esis assured that the observed effects were real and
not dependent on the choice of assay used.
Previous and our ﬁndings therefore support the
view that there is no adverse effect of FDP on human
osteoblasts and MSCs in vitro. Both FDP and TZP are
prepared by different methods of depolymerization
and differ to some extent in their pharmacokinetic
properties and anticoagulant proﬁles. FDP is a syn-
thetically produced pentasaccharide sequence with a
mean molecular weight of 1.728 and half life 17 h,
with only anti-Xa activity and no anti-IIa activity.
27
TZP has a higher molecular weight (4.800), half life
 4 h, and 1.6 anti-Xa/anti-IIa ratio.
28 The effect of
heparin and its derivatives on osteoblast differen-
tiation are molecular weight dependent.
29 Molecular
size has been reported to affect heparin’s afﬁnity for
heparin-binding plasma proteins, as well as endo-
thelial cells and platelets.
30 Although less pronounced
than UFH, TZP shows signiﬁcant binding to endo-
thelial cells and osteoblasts.
31 Osteoblast proliferation
is inﬂuenced by insulin like growth factors (IGFs)
32
and human osteoblasts express a surface binding
for IGFs to which TZP is able to bind and to compete
with IGF. This might explain the impaired regulation
of proliferation and differentiation of osteoblasts
33
and, potentially, MSCs. In contrast, FDP lacks the
modulatory effects of heparin.
34
Moreover, many growth factors and cytokines
thought to modulate vascularization during fracture
healing (ﬁbroblast growth factor, vascular endothelial
growth factor, platelet derived growth factor) are
heparin dependent.
35 Thus, administration of TZP
may alter growth factor bioavailability and activity.
It seems possible that interaction of TZP and
FDP with osteoblast is either quantitatively or
qualitatively different and this reﬂects the diffe-
rences in molecular weight distribution of the two
preparations.
Figure 5. The effects of TZP and FDP on MSC chondrogenesis. day 21 sGAG production by p3 MSCs grown as pellets in ChondroDiff
supplemented with different concentrations of TZP (A) and FDP (B,C). Individual donor-derived cultures are shown at the top and
combined results for all donors (mean   SD) are shown at the bottom. No effect on sGAG production was found using both drugs.
Toluidine Blue staining of chondrogenic pellets in a representative experiment with the addition of FDP is shown in (C). [Color ﬁgure
can be seen in the online version of this article, available at http://wileyonlinelibrary.com/journal/jor]
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from PC to 100-fold higher than their peak PC
were used to determine dose-depended effects. MSC
proliferation and differentiation were assessed using
several parallel end-point studies. In the CFU-F assay,
the direct measurements of the effects of drugs on
most proliferating cells were studied. In the XTT
assay, the reduction of a tetrazolium component (XTT)
into soluble formazan product by the mitochondria
of all viable cells was measured. Smaller inhibition
effects upon the addition of TZP in the XTT assay
compared to CFU-F assay could be explained by above
factors or differences in cell density. The reduced MSC
proliferation following TZP treatment could have
implications for the initial expansion of the MSC pool
during initial stages of fracture healing. This decrease
could further delay the physiological events during
endochondral and intramedullar ossiﬁcation during
healing processes. Using several independent assays
for osteo- and chonrogenesis, no inhibition of MSC
differentiation upon the addition of TZP or FDP was
found. Altogether, these ﬁndings showed that TZP
could be potentially detrimental during early but not
late stages of fracture healing. FDP on the other hand
would not be inhibiting MSC functionality during the
whole fracture healing processes.
In conclusion, this work showed that FDP had
no adverse effects on either MSC proliferation or
osteogenic and chondrogenic differentiation in vitro.
This is reassuring with respect to fracture repair and
bone metabolism but needs ongoing clinical vigilance
and observation to conﬁrm that it is associated with
skeletal health maintenance. Future studies may
include clinical studies of prospective randomized
nature, comparing FDP with other commonly used
anticoagulants.
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